Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01694862
Other study ID # Integra Initiative
Secondary ID
Status Completed
Phase N/A
First received September 21, 2012
Last updated May 13, 2016
Start date January 2009
Est. completion date June 2013

Study information

Verified date May 2016
Source London School of Hygiene and Tropical Medicine
Contact n/a
Is FDA regulated No
Health authority United Kingdom: London School of Hygiene & Tropical Medicine
Study type Interventional

Clinical Trial Summary

The overarching aim of the Integra Initiative is to strengthen the evidence base on the impact of integrating family planning (FP), postnatal care (PNC) and HIV services in sub-Saharan Africa. Specifically, in the study the investigators aim to test the following hypotheses:

the provision of integrated services, compared to separate services, will:

1. lead to increased uptake of a range of SRH services .

2. attract a greater number and diversity of clients.

3. lead to increased quality of a range of SRH services

4. lead to healthier sexual and reproductive behavior.

5. lead to reduced stigma at health facilities.

6. lead to the more efficient use of resources, with a lower unit cost of provision of key services.

For the purposes of this study integration is defined as offering clients both HIV and postnatal care (PNC) or HIV and family planning (FP) services in the same visit.

To better understand how services can be integrated in different countries this study focuses on two key models of integration in Kenya and Swaziland.

- The first model focuses on integration of FP and HIV services (integrated FP model) and entails performing HIV testing, STI screening and management, cervical cancer screening, condom promotion within FP consultations, as well as active referral to antiretroviral (ART) units for HIV-positive clients. The FP model will be evaluated in Kenya only.

- The second model focuses on integration of PNC and HIV services (integrated PNC model) and will be implemented in both Kenya and Swaziland. The model focuses on the provision of PNC services to mother and baby, FP services, repeat HIV testing for mother, HIV testing for infant and referral to HIV services for HIV positive mothers and infants, as well as referrals for clients requiring other additional services.


Description:

There are many well-established reasons that support the rationale for integrating or linking sexual and reproductive health (SRH) and HIV services in developing countries with generalized HIV epidemics - primarily in sub-Saharan Africa. Yet the evidence base for the impact of integrated service delivery on health outcomes and costs remains weak. Partly this is a result of methodological difficulties.

There is an emerging body of literature addressing the challenges of using randomized controlled trials to assess the impact of public health interventions. Particularly in cases such as the Integra Initiative, where the causal chain (between intervention and outcome) is long, and where there are is a broad range of outcomes that need to be explored, and where there is already some a degree of integration occurring in some clinic settings, attempting to conduct a randomized controlled trial is not appropriate. Consistent with evaluation designs described by Habicht and colleagues, the Integra design includes evaluation of performance and impact to try to make two types of causal inference: adequacy and plausibility.

Evaluation of adequacy will assess whether the expected changes in provision, service utilisation and cost-effectiveness have occurred in intervention facilities. Evaluation of impact will assess the plausibility that changes in service, health and behavioral outcomes are due to the Integra Initiative. The case for such plausibility will be built from the following strands of evidence:

- Comparing findings in 'intervention' facilities with those in facilities chosen as 'comparison' sites prior to the evaluation

- Exploring a dose-response relationship between the measured extent of integration and the study outcomes

- Measuring changes in performance over time, to demonstrate a logical sequence between the intervention (integration) and outcomes.

- Measuring change in each step of the logic model - a prerequisite for any attribution to the intervention

- Triangulating findings from a mix of research methods to capture a range of perspectives and insights from different disciplines.

The study will employ a controlled pre- and post-test quasi-experimental, or non-randomised, design and utilises multiple research methods (cohort study, community survey, clinic assessments, costing tools and qualitative interviews). Since the research is being conducted in real-life health delivery settings where programmatic contamination is possible due to ongoing health programme interventions over the study period, the control group will be referred to as a 'comparison group', for which outcomes will be compared over time up to two years after implementation.


Recruitment information / eligibility

Status Completed
Enrollment 4763
Est. completion date June 2013
Est. primary completion date December 2012
Accepts healthy volunteers No
Gender Female
Age group 15 Years to 49 Years
Eligibility Inclusion Criteria for FP-HIV study:

- women aged 15 years and over,

- be revisit FP clients,

- be living in the catchment area of the health facility, and

- willing to give their informed consent to be interviewed.

Inclusion Criteria for PNC-HIV study:

- women aged 15 years and over,

- be postnatal clients attending a postnatal check for themselves and/or their infant (0-10 weeks),

- living in the catchment area of the health facility, and

- willing to give their informed consent to be interviewed.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research


Related Conditions & MeSH terms


Intervention

Procedure:
Integrated FP/PNC service delivery
The intervention uses a procedural tool building on existing MoH procedures. It has nine components: strengthening protocols, guidelines and training materials for integrated HIV-SRH care; training, mentorship; developing a mentoring and supervisory package; improving provider capacity; ensuring availability of minimum levels of equipment and supplies for integrated services; support supervision; organizational change (including reviewing use of available rooms) and role clarification; improving availability of IEC/BCC materials on FP and HIV; strengthening the referral system between FP and ART and the data collection and recording systems.

Locations

Country Name City State
Kenya Multiple MoH facilities in Kenya Thika, Nyeri and others
Swaziland Multiple MoH locations in Swaziland Manzini

Sponsors (4)

Lead Sponsor Collaborator
London School of Hygiene and Tropical Medicine Bill and Melinda Gates Foundation, International Planned Parenthood Federation, Population Council

Countries where clinical trial is conducted

Kenya,  Swaziland, 

Outcome

Type Measure Description Time frame Safety issue
Other Unit costs Economics measures in 42 study clinics:
Cost per eligible client receiving ART,
Cost per person-month of receiving ART
Cost per client counseled, tested and receiving results
Cost per client receiving each service component
24 months No
Primary Unintended pregnancies Unintended pregnancy measures:
percent women who become pregnant (cohort study)
percent HIV+/HIV- women reporting planned pregnancy (cohort and client exit interviews)
percent clients women with correct knowledge of fertile period (cohort, client exit interviews) Proportion of population who report unintended pregnancy in last 12 months (community survey)
24 months No
Secondary HIV risk behaviour HIV risk measures:
Condom use at last sex (cohort, client exit interviews, community survey)
Number of partners in past 12 months (cohort, client exit interviews, community survey)
Received STI/HIV counseling (cohort, client exit interviews, community survey) Consistent condom use reported (cohort, client exit interviews, community survey)
Use of condoms with another FP method (dual protection )(cohort, client exit interviews, community survey)
24 months No
See also
  Status Clinical Trial Phase
Recruiting NCT06162897 - Case Management Dyad N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT02528773 - Efficacy of ART to Interrupt HIV Transmission Networks
Recruiting NCT05454839 - Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
Recruiting NCT05322629 - Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women N/A
Completed NCT02579135 - Reducing HIV Risk Among Adolescents: Evaluating Project HEART N/A
Active, not recruiting NCT01790373 - Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence N/A
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Completed NCT04039217 - Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM Phase 4
Active, not recruiting NCT04519970 - Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) N/A
Completed NCT04124536 - Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women N/A
Recruiting NCT05599581 - Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health N/A
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Completed NCT02758093 - Speed of Processing Training in Adults With HIV N/A
Completed NCT02500446 - Dolutegravir Impact on Residual Replication Phase 4
Completed NCT03805451 - Life Steps for PrEP for Youth N/A
Active, not recruiting NCT03902431 - Translating the ABCS Into HIV Care N/A
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2

External Links